<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Classification and epidemiology of anal cancer</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Classification and epidemiology of anal cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Classification and epidemiology of anal cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Christopher G Willett, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard M Goldberg, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sonali M Shah, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Anal cancer is uncommon, with less than 1000 new cases diagnosed annually in the United States [<a href="#rid1">1</a>]. Data on worldwide incidence are available from the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fgco.iarc.fr%2Ftoday%2Fhome&amp;token=o1j24x8yqbCigYycIC6ni4B7VDe7Hz17hJNfy5f8gT3%2F1GKAFN45f%2BlZyQqB2Xd7&amp;TOPIC_ID=2474" target="_blank">GLOBOCAN database</a>.</p><p>The incidence of anal cancer in the general population has increased over several decades, both in the United States and elsewhere. An increased incidence has been associated with female sex, infection with human papillomavirus (HPV), lifetime number of sexual partners, genital warts, cigarette smoking, receptive anal intercourse, and infection with HIV [<a href="#rid2">2</a>]. Thus, from an etiologic standpoint, anal cancer is more similar to genital malignancies than it is to gastrointestinal tract cancers.</p><p>The pathology and epidemiology of anal cancer will be reviewed here. The clinical features, diagnosis, and treatment are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2469.html" rel="external">"Clinical features and staging of anal cancer"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">ANATOMY AND TYPES OF TUMORS</span><span class="headingEndMark"> — </span>The anal canal is 2.5 to 3.5 cm long. It begins where the rectum enters the puborectalis sling at the apex of the anal sphincter complex (palpable as the anorectal ring on digital rectal examination and approximately 1 to 2 cm proximal to the dentate line) and ends where the squamous mucosa blends with the perianal skin, which roughly coincides with the palpable intersphincteric groove or the outermost boundary of the internal sphincter muscle  (<a class="graphic graphic_figure graphicRef62539" href="/z/d/graphic/62539.html" rel="external">figure 1</a>). Externally, the anal canal is surrounded by the internal and external anal sphincter muscles  (<a class="graphic graphic_figure graphicRef62539" href="/z/d/graphic/62539.html" rel="external">figure 1</a>) [<a href="#rid3">3</a>]. The anal canal is divided by the dentate (pectinate) line, a macroscopically visible landmark that overlies the transition from glandular to squamous mucosa; immediately proximal to the dentate line, a narrow zone of transitional mucosa that is similar to urothelium is variably present.</p><p>The proximal region of the anus encompasses mucosa of three different histologic types: glandular, transitional, and nonkeratinizing squamous (proximal to distal, respectively). Distally, the squamous mucosa (which is devoid of epidermal appendages, such as hair follicles, apocrine glands, and sweat glands) merges with the perianal skin (true epidermis). This mucocutaneous junction has been referred to as the anal "verge" or margin. This boundary is indistinct on macroscopic examination, and anatomically, its location may vary with the patient's body habitus.</p><p>As a result, four distinct categories of tumors arise in the anal region:</p><p class="bulletIndent1"><span class="glyph">●</span>Tumors that develop from any of the three types of mucosa, which cannot be visualized in their entirety while gentle traction is placed on the buttocks, are termed anal cancers [<a href="#rid3">3</a>]: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Tumors arising in the transitional or squamous mucosa are squamous cell cancers (SCCs) and appear to behave similarly, despite their sometimes variable morphologic appearance. By convention, most series that report outcomes of "anal cancer" refer exclusively to these tumors. The term "anal cancer," by common definition, refers to SCCs arising within the mucosa of the anus, and the two terms will be used interchangeably throughout this review.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Basaloid (also termed junctional or cloacogenic) carcinoma is a variant of SCC that arises from the epithelial transitional zone. However, these terms have largely been abandoned because these tumors are now recognized as nonkeratinizing types of SCC. Tumors arising within the anal canal above the dentate line are often nonkeratinizing SCCs, while those arising within the anal canal distal to the pectinate (dentate) line are often keratinizing.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adenocarcinomas arising from glandular elements within the anal canal are rare, but they appear to share a similar natural history to rectal adenocarcinomas and are treated similarly, with resection plus either preoperative or postoperative chemoradiotherapy. (See  <a class="medical medical_review" href="/z/d/html/123063.html" rel="external">"Treatment of anal cancer", section on 'Anal adenocarcinoma'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tumors arising within the hair-bearing skin at or distal to the squamous mucocutaneous junction have been referred to as anal margin cancers. However, the most recent (eighth) edition of the American Joint Committee on Cancer (AJCC) cancer staging manual and the fifth edition of the World Health Organization (WHO) classification of tumors of the digestive system define tumors that arise within the skin at or distal to the squamous mucocutaneous junction that can be seen in their entirety with gentle traction placed on the buttocks and are within 5 cm of the anus as perianal skin cancers [<a href="#rid3">3,4</a>]. In practice, perianal skin cancers are rare. Most are treated similarly to anal canal cancers, with radiation therapy (RT) and concurrent chemotherapy. However, local treatment (surgery or local RT [electrons]) is used only when the lesion is very separate from the anal verge and is a discrete skin lesion. (See  <a class="medical medical_review" href="/z/d/html/123063.html" rel="external">"Treatment of anal cancer", section on 'True perianal skin cancers'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary rectal SCCs, which are very rare, can be difficult to distinguish from anal cancers. They are generally treated according to the same approach as anal cancer. (See  <a class="medical medical_review" href="/z/d/html/123063.html" rel="external">"Treatment of anal cancer", section on 'Rectal squamous cell cancers'</a>.)</p><p></p><p class="headingAnchor" id="H3"><span class="h2">Histology</span><span class="headingEndMark"> — </span>Several histologic types of epithelial malignancy arise within the anus, including SCCs (which are the most common), adenocarcinomas, and neuroendocrine tumors  (<a class="graphic graphic_table graphicRef122451" href="/z/d/graphic/122451.html" rel="external">table 1</a>). Due to the variation in anatomy (particularly the transition zone), the anal canal can be quite short in length in some individuals, and the anatomical location as determined by a surgeon or endoscopist should not determine the classification of a tumor. Rather, the histology and location of tumors in the anal region guide the appropriate diagnosis and treatment.</p><p class="headingAnchor" id="H4"><span class="h3">Anal canal tumors</span><span class="headingEndMark"> — </span>There is no easily identifiable landmark between the rectum and the anus; in addition, the transition zone has a widely variable histologic appearance. As a result, the pathologic classification of tumors arising in this area may be difficult.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Squamous cell cancer</strong> – Tumors arising in the transitional or squamous mucosa are SCCs and appear to behave similarly, despite their sometimes variable morphologic appearance [<a href="#rid5">5,6</a>]. By convention, most series that report outcomes of "anal cancer" refer exclusively to these tumors. The term "anal cancer," by common definition, refers to SCCs arising within the mucosa of the anus, and the two terms will be used interchangeably throughout this review.</p><p></p><p class="bulletIndent1">Basaloid features are identified in approximately 25 percent of SCCs of the anal canal and must be distinguished from basal cell carcinomas of the perianal skin, which as noted below, are classified as skin cancers. Basaloid (also termed junctional or cloacogenic) carcinoma is a variant of SCC that arises from epithelial transitional zone. However, these terms have largely been abandoned because these tumors are now recognized as nonkeratinizing types of SCC. Tumors arising within the anal canal above the dentate line are termed nonkeratinizing SCCs, while those arising within the anal canal distal to the dentate line are termed keratinizing SCCs.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adenocarcinomas</strong> – Adenocarcinomas arising from glandular elements within the anal canal are rare, but they appear to share a similar natural history to rectal adenocarcinomas and are treated similarly. (See  <a class="medical medical_review" href="/z/d/html/123063.html" rel="external">"Treatment of anal cancer", section on 'Anal adenocarcinoma'</a>.)</p><p></p><p>Determination of the anatomic site of origin of carcinomas that overlap the anorectal junction can be problematic, particularly since the rectal mucosa may extend to within 1 to 2 cm of the anal verge.</p><p class="headingAnchor" id="H5"><span class="h3">Perianal skin cancers</span><span class="headingEndMark"> — </span>The clinical distinction between tumors of the anal canal and those that involve the anal "margin" or perianal skin can also be difficult. As noted above, SCCs that arise on any mucosal surface of the anus are treated as anal canal cancers, even if they are located distally at the perianal margin. In contrast, tumors arising within the hair-bearing skin at or distal to the squamous mucocutaneous junction have been termed anal margin cancers. However, the preferred term is perianal skin cancer, since with the exception of melanomas, tumors arising within the perianal skin behave biologically like skin cancers. Although there are essentially no prospective data validating this practice, these tumors had been classified and staged as skin cancers, rather than anal canal cancers, until more recently [<a href="#rid7">7</a>]. The most recent (eighth) edition of the AJCC cancer staging manual and the most recent (fifth) edition of the WHO classification of tumors depart from this practice and stage perianal skin cancers the same as anal cancers  (<a class="graphic graphic_table graphicRef110681" href="/z/d/graphic/110681.html" rel="external">table 2</a>) [<a href="#rid3">3</a>].</p><p>Most clinicians treat SCC lesions of the perianal skin similarly to anal canal cancers, using RT and concurrent chemotherapy. Local treatment (surgery, or local RT [electrons]) is appropriate when the lesion is very separate from the anal verge and is a discrete skin lesion. However, it can be very difficult to distinguish between tumors arising on the hair-bearing skin or within the anus/anal cancer. In practice, the distinction between perianal skin cancers and anal canal/margin cancers can be difficult, and the default management by most clinicians is to assume that these are anal margin/canal cancers if there is any doubt, and to treat with initial chemoradiotherapy rather than local therapy alone. (See  <a class="medical medical_review" href="/z/d/html/123063.html" rel="external">"Treatment of anal cancer", section on 'True perianal skin cancers'</a>.)</p><p>Tumors of the perianal skin are most often SCCs, but other types of cutaneous malignancies (eg, basal cell carcinoma, melanoma, Bowen disease, extramammary Paget disease) can arise within this region.</p><p class="bulletIndent1"><span class="glyph">●</span>Bowen disease (SCC in situ) can occur within the perianal skin as it can in other areas of non-sun-exposed skin. (See  <a class="medical medical_review" href="/z/d/html/16225.html" rel="external">"Cutaneous squamous cell carcinoma (cSCC): Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Melanomas that arise in either the anal canal or perianal skin should be treated according to the same principles commonly applied to this tumor at other sites. (See  <a class="medical medical_review" href="/z/d/html/7620.html" rel="external">"Surgical management of primary cutaneous melanoma or melanoma at other unusual sites"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Paget disease of the anus, an intraepithelial adenocarcinoma, can be one of two types: a primary cutaneous malignancy in which the tumor cells show sweat gland differentiation, and a lesion in which there is involvement of adjacent squamous epithelium by lateral intramucosal/intraepithelial spread from an underlying adenocarcinoma of the rectum or perianal glands.</p><p></p><p class="headingAnchor" id="H6"><span class="h2">Lymphatic drainage</span><span class="headingEndMark"> — </span>Lymphatic drainage of anal canal and perianal skin cancers is dependent upon the anatomic site of origin  (<a class="graphic graphic_figure graphicRef62539" href="/z/d/graphic/62539.html" rel="external">figure 1</a>) [<a href="#rid8">8-10</a>]. Tumors originating above the dentate line, similar to rectal cancers, drain to the mesorectal and internal iliac nodes. In contrast, tumors arising below the dentate line may also spread to the superficial inguinal and external iliac (deep inguinal) nodes. In contrast to earlier editions, in the eighth edition of the AJCC/Union for International Cancer Control (UICC) staging system, metastases in the inguinal, mesorectal, internal, or external iliac are all considered N1 nodes  (<a class="graphic graphic_table graphicRef110681" href="/z/d/graphic/110681.html" rel="external">table 2</a>).</p><p class="headingAnchor" id="H7"><span class="h1">EPIDEMIOLOGY AND RISK FACTORS</span><span class="headingEndMark"> — </span>Although it remains an uncommon cancer, the incidence of anal cancer is increasing in the United States and other countries [<a href="#rid11">11-16</a>]. In data derived from the United States Cancer Statistics dataset, between 2001 and 2015, incidence rates (IR) for anal squamous cell cancer (SCC) increased 2.7 percent per year, and the most pronounced increases were in young Black males and older females between the ages of 60 and 69 [<a href="#rid16">16</a>]. Stage distribution also changed over this time frame, with a tripling in the incidence of distant-stage disease (annual percentage change in males 8.6 percent and in females 7.5 percent) and a doubling of regional (nodal)-stage disease. The analysis also revealed a concomitant increase in mortality over this same time period (3.1 percent increase per year), with significant increases in groups age 50 and older. The reasons underlying the increased incidence and mortality remain unclear, but anal cancer is one of the fastest accelerating causes of cancer incidence and mortality in the United States, and it may surpass cervical cancer to become the leading human papillomavirus (HPV)-linked cancer in older adult females.</p><p>In certain populations, such as males who have sex with other males (MSM) and HIV-infected patients, there is an especially high incidence of anal cancer. The rate of anal cancer was estimated to be as high as 37 per 100,000 among MSM prior to the HIV epidemic [<a href="#rid17">17</a>], rendering its incidence in this population similar to that of cervical cancer in females prior to the introduction of cervical Papanicolaou (Pap) smear screening [<a href="#rid6">6</a>]. The incidence of anal cancer among HIV positive MSM has been estimated to be approximately twice that of HIV negative MSM [<a href="#rid18">18,19</a>].</p><p>In contrast to other common malignancies affecting HIV positive individuals (eg, Kaposi sarcoma and non-Hodgkin lymphoma), the incidence of anal cancer has not declined in the era of potent antiretroviral therapy (formerly referred to as highly active antiretroviral therapy [HAART]) [<a href="#rid20">20,21</a>]. This was demonstrated in a study in San Francisco County, in which the age-adjusted incidence of anal cancer in males 40 to 64 years of age (regardless of sexual orientation) more than quadrupled from the pre-HIV period (1973 to 1978) to the present era (1996 to 1999) following the widespread availability of potent antiretroviral therapy [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/z/d/html/8036.html" rel="external">"HIV infection and malignancy: Management considerations"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Risk factors</span><span class="headingEndMark"> — </span>Certain population groups are known to have a higher than average anal cancer risk, namely persons living with HIV (PLWH), MSM, females diagnosed with human papillomavirus (HPV)-related gynecologic precursor lesions or cancer, solid organ transplant recipients, and individuals with certain autoimmune disorders.</p><p class="headingAnchor" id="H9"><span class="h3">Sexual activity and sexually transmitted infections</span><span class="headingEndMark"> — </span>Initial reports suggesting an increased incidence of the disease in MSM provided a link between sexual activity and the development of anal cancer [<a href="#rid17">17,23</a>]. This relationship has been confirmed in subsequent reports, and linked, in many cases, with sexually transmitted infection, as illustrated by the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span>In a population-based case-control study, females with anal cancer were more likely than controls to have a history of genital warts (relative risk [RR] 32.5), herpes simplex 2 (RR 4.1), or chlamydia trachomatis (RR 2.3), while males with anal cancer were more likely than controls to have never been married (RR 8.6), to have a sexual encounter with another male (ever) (RR 50), to have ever practiced receptive anal intercourse (RR 33), and to have a history of genital warts (RR 27) or gonorrhea (RR 17) [<a href="#rid24">24</a>]. Subsequent studies confirmed the relationship between anal cancer and receptive anal intercourse in males [<a href="#rid25">25-29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A second case-control study in heterosexual individuals compared 417 patients with anal cancer, 534 patients with rectal cancer, and 554 normal controls [<a href="#rid30">30</a>]. In multivariate analysis, the strongest risk factors for anal cancer in females were 10 or more lifetime sexual partners (RR 4.5) and a history of anal warts (RR 11.7), genital warts (RR 4.6), gonorrhea (RR 3.3), cervical dysplasia (RR 2.3), or sexual partners with a history of a sexually transmitted disease (RR 2.4). A history of engaging in receptive anal intercourse before the age of 30 and at least two anal intercourse partners were also significant risk factors in females. Among heterosexual males, multivariate analysis revealed significantly elevated risks of anal cancer with 10 or more lifetime sexual partners (RR 2.5), a history of anal warts (RR 4.9), or a history of syphilis or hepatitis (RR 4.0).</p><p></p><p>HPV and HIV infection are likely responsible for much of this association. However, at least in MSM, there is an elevated risk of anal cancer even amongst those without HIV infection. In a meta-analysis of anal cancer incidence by risk group, the summary IR (cases per 100,000 person-years) for anal cancer were significantly higher for HIV-positive MSM (n = 7 studies, 2,229,234 person-years, IR 85, 95% CI 82-89) but still elevated for HIV-negative MSM (n = 2 studies, 48,135 person-years, IR 19, 95% CI 10-36) [<a href="#rid31">31</a>].</p><p class="headingAnchor" id="H10"><span class="h3">Human papillomavirus infection</span><span class="headingEndMark"> — </span>HPV infection is the most commonly diagnosed sexually transmitted disease in the United States and provides as least part of the link between sexual activity and anal cancer. A close association exists between infection by oncogenic HPV strains and many premalignant and malignant lesions of the genital tract, anus, and rectum [<a href="#rid30">30,32</a>]. Furthermore, HPV infection is the common link that explains the association between index and second primary anogenital cancers and oral cavity/pharyngeal cancers. (See  <a class="medical medical_review" href="/z/d/html/8031.html" rel="external">"Virology of human papillomavirus infections and the link to cancer"</a> and  <a class="medical medical_review" href="/z/d/html/3378.html" rel="external">"Epidemiology, staging, and clinical presentation of human papillomavirus associated head and neck cancer", section on 'Epidemiology'</a> and  <a class="medical medical_review" href="/z/d/html/3405.html" rel="external">"Second primary malignancies in patients with head and neck cancers", section on 'Incidence'</a>.)</p><p>HPV DNA has been isolated from 46 to 100 percent of in situ and invasive SCCs of the anus [<a href="#rid30">30,33-35</a>], and epidemiologic studies have shown that up to 93 percent of anal SCCs are associated with HPV infection. Females are more likely to have HPV associated anal cancer than are males [<a href="#rid36">36</a>]. HPV 16 presence is also associated with a better prognosis [<a href="#rid37">37</a>].</p><p>While a number of HPV types can be found in the anogenital tract, only a few have been associated with cancer. The spectrum of HPV types in the anal canal is similar to that described in the cervix and is associated with the same "risk" phenotypes. As in cervical cancer, HPV 16 is the most frequently isolated type in anal malignancies [<a href="#rid30">30,35,38,39</a>], and its presence predicts for preinvasive as well as invasive cancer. HPV 16 associated anal SCC can be identified histologically by immunohistochemical expression of p16 [<a href="#rid37">37</a>]. In contrast, low-grade in situ lesions frequently are associated with other HPV subtypes [<a href="#rid29">29,39,40</a>].</p><p>The premalignant condition of cervical intraepithelial neoplasia (CIN or squamous intraepithelial lesions [SIL]) associated with HPV infection of the cervix also occurs with HPV infections involving the anus (termed anal SIL, previously called anal intraepithelial neoplasia [AIN]). Both cervical SIL and anal SIL can be morphologically low grade or high grade. The sometimes confusing terminology associated with anal squamous dysplasia is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/8032.html" rel="external">"Anal squamous intraepithelial lesions: Epidemiology, clinical presentation, diagnosis, screening, prevention, and treatment", section on 'Histopathology and nomenclature'</a>.)</p><p>HPV infection in the anal canal and perianal region may be subclinical or clinically apparent as condylomata. SIL, particularly high-grade SIL, is considered to be the precursor of anal cancer. Progression of high-grade SIL to invasive anal SCC is related to many factors, including HIV seropositivity, a lower CD4 count, the type of HPV infection, and higher levels of DNA of high-risk HPV types in the anal canal [<a href="#rid41">41</a>]. (See  <a class="medical medical_review" href="/z/d/html/8032.html" rel="external">"Anal squamous intraepithelial lesions: Epidemiology, clinical presentation, diagnosis, screening, prevention, and treatment", section on 'Natural history'</a>.)</p><p>The prevalence of HPV infection in MSM, a group at high risk for both high-grade SIL and invasive anal cancer, is higher in the presence of HIV infection [<a href="#rid42">42</a>]. (See <a class="local">'HIV infection'</a> below.)</p><p>A substantial minority of anal cancers are not associated with HPV infection. No difference has been noted between HPV positive and HPV negative tumors in regards to patient age, the presence of adjacent dysplasia, ductal differentiation, or prognosis [<a href="#rid43">43</a>].</p><p>Vaccines directed against the HPV types associated with cervical and anal neoplasia in females and anal lesions in males have been developed, and their utility for prevention of anal neoplasia is beginning to be studied. As an example, in a randomized trial involving 4065 males, a quadrivalent HPV vaccine was effective in preventing infection with HPV types 6, 11, 16, and 18 and preventing the development of external genital lesions.</p><p>In a planned substudy of that trial evaluating the impact of the quadrivalent vaccine on the development of SIL in 602 MSM, there was a 78 percent decrease in the incidence of SIL associated with HPV types 6, 11, 16, and 18 among males who received all three vaccine doses compared with placebo [<a href="#rid44">44</a>]. The results of this trial and recommendations for the use of HPV vaccines are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/8032.html" rel="external">"Anal squamous intraepithelial lesions: Epidemiology, clinical presentation, diagnosis, screening, prevention, and treatment", section on 'Prevention'</a> and  <a class="medical medical_review" href="/z/d/html/8325.html" rel="external">"Human papillomavirus vaccination"</a>.)</p><p class="headingAnchor" id="H11"><span class="h3">HIV infection</span><span class="headingEndMark"> — </span>It is unclear whether HIV infection itself has a direct effect on the development of anal cancer or if this is mediated through HPV. The data supporting a relationship between HIV, HPV, and anal cancer include the following observations:</p><p class="bulletIndent1"><span class="glyph">●</span>Epidemiologic data indicate that the increasing anal cancer rates in the United States were strongly influenced by the HIV epidemic in males but were independent of HIV infection in females [<a href="#rid13">13,45</a>]. Data are available from an analysis of the HIV/AIDS Cancer Match (HACM) study, a registry-based cohort study linking 12 population-based HIV and cancer registries; these 12 United States regions represent nearly one-third of the United States population, and 44 percent of people living with HIV (PLWH) reside in these 12 regions [<a href="#rid45">45</a>]. Between 2001 and 2015, there were an estimated 16,110 anal SCC cases in these 12 regions, with an estimated 6277 occurring in males and 9833 occurring in females; 14.5 percent of all cases occurred in PLWH. In 2013 to 2015, 33 percent of anal cancers among males occurred in PLWH, but only 3 percent among females. The percentage of anal SCCs among males with HIV increased from 29.1 to 34.9 percent between 2001 and 2015, while for females with HIV the percentage remained stable (2.6 percent in 2001-2004, compared with 2.3 percent in 2013-2015).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is a markedly higher incidence of SIL and anal cancer in males living with HIV (MLWH), particularly MSM who are living with HIV (MSMLWH) [<a href="#rid42">42,46-49</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a report of data from 13 cohorts (11 clinic-based, including 34,189 HIV infected and 114,260 HIV uninfected individuals) that were included in the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) for the years 1996 to 2007, the unadjusted anal cancer IR per 100,000 person-years were 131 for MSMLWH, 46 for other MLWH, and 2 for MSM without HIV [<a href="#rid49">49</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a meta-analysis of anal cancer incidence by risk group, the summary IR (cases per 100,000 person-years) for anal cancer were significantly higher for MSMLWH (n = 7 studies, 2,229,234 person-years, IR 85, 95% CI 82-89) compared with MLWH but not practicing MSM (n = 5 studies, 1,626,448 person-years, IR 32, 95% CI 30-35) [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The incidence of HPV infection and HPV associated preinvasive and invasive malignancy is higher in people living with HIV (PLWH), regardless of sexual practice [<a href="#rid29">29,50-54</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among HPV infected individuals, the prevalence of high-grade SIL and anal carcinoma is higher in PLWH compared with those without HIV [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of 53 studies, the prevalence of both high-risk anal HPV subtypes (74 versus 34 percent) and anal cancer (45.9 versus 5.1 per 100,000 men) was significantly higher among MSMLWH as compared with MSM without HIV [<a href="#rid42">42</a>].</p><p></p><p>Despite these observations, the overall impact of HIV infection on IR of anal cancer remains unclear, since population-based studies have produced conflicting results [<a href="#rid13">13,18,19,56-58</a>]. The following observations illustrate the range of findings:</p><p class="bulletIndent1"><span class="glyph">●</span>An increased incidence of anal cancer was noted in some reports during the peak of the AIDS epidemic [<a href="#rid57">57</a>]. In New York City, for example, there was a 10-fold increase in the incidence of anal cancer among males age 20 to 49 from 1979 to 1985, concurrent with the onset of the AIDS epidemic and a marked rise in Kaposi sarcoma and non-Hodgkin lymphoma in this population [<a href="#rid57">57</a>]. In contrast, case-control studies of single males living in San Francisco did not find a significant rise in the incidence of anal cancer from before the appearance of AIDS in about 1980 to the late 1980s, a period in which there was an increased incidence of both Kaposi sarcoma and non-Hodgkin lymphoma [<a href="#rid28">28,59,60</a>]. (See  <a class="medical medical_review" href="/z/d/html/8036.html" rel="external">"HIV infection and malignancy: Management considerations"</a> and  <a class="medical medical_review" href="/z/d/html/8035.html" rel="external">"HIV infection and malignancy: Epidemiology and pathogenesis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an American series linking registries reporting both AIDS and cancer, the RR of developing anal cancer in PLWH was much higher than that in the general population (standardized incidence ratio 19.1, 95% CI 18.1-20.0) [<a href="#rid61">61</a>]. The anal cancer incidence was highest among MSM, with increased age, and in those with AIDS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>PLWH who have a longer duration of HIV infection have a substantially higher rate of anal cancer, but in contrast to other AIDS-associated cancers, the use of potent antiretroviral therapy has not led to a decline in the incidence of anal cancer [<a href="#rid62">62,63</a>].</p><p></p><p>Without controlling for receptive anal intercourse and prior HPV infection, it is difficult to discern the true effect of HIV on the incidence of anal cancer. It is possible that HIV infection interacts with HPV to predispose to anal cancer. In a cohort of 346 MSMLWH and 262 MSM without HIV, infection with multiple anal HPV types was more common in the MSMLWH (73 versus 23 percent) and was associated with significant immunosuppression (CD4 count below 200/microL) [<a href="#rid64">64</a>]. This finding could reflect increased HPV replication in patients with AIDS, which would allow more HPV types to reach a detectable concentration. Infection with more than one type of HPV is associated with an increased risk of abnormal anal cytology [<a href="#rid46">46,65</a>]. (See  <a class="medical medical_review" href="/z/d/html/8031.html" rel="external">"Virology of human papillomavirus infections and the link to cancer"</a>.)</p><p>Chronic immunosuppression in HIV infection is also associated with a higher risk of anal cancer and of progression from low-grade SIL to high-grade SIL or invasive cancer [<a href="#rid29">29,41,66</a>]. As an example, within a nested case-control study in the Swiss HIV cohort study, low CD4 counts were significantly associated with anal cancer, both at nadir and at the time of cancer diagnosis [<a href="#rid66">66</a>]. The influence of CD4 counts appeared to be strongest six to seven years prior to the diagnosis of anal cancer (odds ratio for &lt;200 versus ≥500 cells/microL 14.0, 95% CI 3.85-50.9).</p><p class="headingAnchor" id="H12"><span class="h3">Chronic immunosuppression not due to HIV</span></p><p class="headingAnchor" id="H3143909450"><span class="h4">Solid organ transplant recipients</span><span class="headingEndMark"> — </span>Other causes of chronic immunosuppression, such as solid organ transplantation, also may be associated with the development of high-grade SIL and invasive anal carcinoma [<a href="#rid31">31,67-69</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>In a meta-analysis of anal cancer incidence by risk group, the summary IR (cases per 100,000 person-years) for anal cancer among solid organ transplant recipients (n = 5 studies, 1,946,206 person-years, IR 13, 95% CI 12-15) [<a href="#rid31">31</a>]. By ten years post-transplant, this IR reached 24.5 for males and 49.6 for females.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among renal transplant recipients, the risk of anogenital cancer may be increased as much as 100-fold; this high risk level has been associated with persistent HPV infection [<a href="#rid68">68,69</a>].</p><p></p><p>This subject of post-transplantation malignancy is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/7304.html" rel="external">"Malignancy after solid organ transplantation"</a>.)</p><p class="headingAnchor" id="H2260405133"><span class="h4">Other immunocompromised patients</span><span class="headingEndMark"> — </span>Autoimmune disease also is a risk factor for subsequent anal cancer, in part related to treatment with chronic glucocorticoid therapy [<a href="#rid70">70,71</a>]. In a meta-analysis of anal cancer incidence by risk group, the summary IR (cases per 100,000 person-years) for anal cancer among individuals with systemic lupus erythematosus was 10 (95% CI 5-19), for ulcerative colitis it was 6 (95% CI 3-11), and for Crohn's disease it was 3 (95% CI 2-4). (See  <a class="medical medical_review" href="/z/d/html/7988.html" rel="external">"Major adverse effects of systemic glucocorticoids"</a>.)</p><p class="headingAnchor" id="H13"><span class="h3">Cigarette smoking</span><span class="headingEndMark"> — </span>Several case-control studies have noted a statistically significant risk of anal cancer in smokers, especially current smokers [<a href="#rid25">25,35,66,72-75</a>]. In one series, cigarette smoking was associated with a significantly increased risk of anal cancer (RR 1.9 for 20 pack-years, RR 5.2 for 50 pack-years) [<a href="#rid25">25</a>]. Cigarette smoking is highly associated with cervical neoplasia and is thought to act as a cocarcinogen for anogenital SCC [<a href="#rid76">76</a>]. (See  <a class="medical medical_review" href="/z/d/html/3219.html" rel="external">"Cervical cancer screening tests: Techniques for cervical cytology and human papillomavirus testing"</a>.)</p><p class="headingAnchor" id="H25435714"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/16831.html" rel="external">"Patient education: Anal cancer (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H18017504"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anatomy and tumor types</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Four distinct categories of tumors arise in the anal region (see <a class="local">'Anatomy and types of tumors'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Tumors that develop from any of the three types of lining mucosa (glandular, transitional, and squamous) that cannot be visualized in their entirety while gentle traction is placed on the buttocks are termed anal canal cancers. The vast majority are squamous cell cancers (SCCs). (See <a class="local">'Anatomy and types of tumors'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Perianal skin cancers arise within the hair-bearing skin at or distal to the squamous mucocutaneous junction; by definition, they can be seen in their entirety with gentle traction placed on the buttocks and are within 5 cm of the anus as perianal skin cancers.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Adenocarcinomas are thought to arise from glandular elements within the anal canal.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Primary rectal SCCs, which are very rare, can be difficult to distinguish from anal cancers.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The majority of tumors arising in the transitional or squamous mucosa of the anal canal are SCCs. The term "anal cancer," by common definition, refers to SCCs arising within the mucosa of the anal canal. In contrast, adenocarcinomas arising from glandular elements within the anal canal are rare but appear to share a similar natural history to rectal adenocarcinomas. They are treated in a manner that is similar to rectal carcinoma rather than anal cancer. (See <a class="local">'Anal canal tumors'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology and risk factors</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Although it remains an uncommon cancer, the incidence of anal cancer is increasing in the United States and other countries. (See <a class="local">'Epidemiology and risk factors'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>An increased incidence has been associated with sexual activity, including anal receptive intercourse and the lifetime number of sexual partners; infection with human papillomavirus (HPV); infection with HIV; other causes of chronic immunosuppression, including solid organ transplantation, and cigarette smoking. Thus, from an etiologic standpoint, anal cancer is more similar to genital malignancies than it is to gastrointestinal tract cancers. (See <a class="local">'Risk factors'</a> above.)</p><p></p><p class="headingAnchor" id="H890158581"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges David P Ryan, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023; 73:17.</a></li><li><a class="nounderline abstract_t">Damgacioglu H, Lin YY, Ortiz AP, et al. State Variation in Squamous Cell Carcinoma of the Anus Incidence and Mortality, and Association With HIV/AIDS and Smoking in the United States. J Clin Oncol 2023; 41:1228.</a></li><li class="breakAll">Welton ML, Steele SR, Goodman KA, et al. Anus. In: AJCC Cancer Staging Manual, 8th ed, Amin MB (Ed), AJCC, Chicago 2017. p.275.</li><li class="breakAll">Lam AK, Goldblum JR. Tumours of the anal canal: Introduction. In: WHO Classification of Tumours: Digestive System Tumours, 5th ed, WHO Classification of Tumours Editorial Board (Ed), International Agency for Research on Cancer, Lyon 2019.</li><li><a class="nounderline abstract_t">Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996; 14:2527.</a></li><li><a class="nounderline abstract_t">Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997; 15:2040.</a></li><li class="breakAll">American Joint Committee on Cancer Staging Manual, 7th ed, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.301.</li><li><a class="nounderline abstract_t">Frost DB, Richards PC, Montague ED, et al. Epidermoid cancer of the anorectum. Cancer 1984; 53:1285.</a></li><li><a class="nounderline abstract_t">Pintor MP, Northover JM, Nicholls RJ. Squamous cell carcinoma of the anus at one hospital from 1948 to 1984. Br J Surg 1989; 76:806.</a></li><li><a class="nounderline abstract_t">Greenall MJ, Quan SH, Stearns MW, et al. Epidermoid cancer of the anal margin. Pathologic features, treatment, and clinical results. Am J Surg 1985; 149:95.</a></li><li><a class="nounderline abstract_t">Johnson LG, Madeleine MM, Newcomer LM, et al. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer 2004; 101:281.</a></li><li><a class="nounderline abstract_t">Robinson D, Coupland V, Møller H. An analysis of temporal and generational trends in the incidence of anal and other HPV-related cancers in Southeast England. Br J Cancer 2009; 100:527.</a></li><li><a class="nounderline abstract_t">Shiels MS, Pfeiffer RM, Chaturvedi AK, et al. Impact of the HIV epidemic on the incidence rates of anal cancer in the United States. J Natl Cancer Inst 2012; 104:1591.</a></li><li><a class="nounderline abstract_t">Cook MB, Dawsey SM, Freedman ND, et al. Sex disparities in cancer incidence by period and age. Cancer Epidemiol Biomarkers Prev 2009; 18:1174.</a></li><li><a class="nounderline abstract_t">Islami F, Ferlay J, Lortet-Tieulent J, et al. International trends in anal cancer incidence rates. Int J Epidemiol 2016.</a></li><li><a class="nounderline abstract_t">Deshmukh AA, Suk R, Shiels MS, et al. Recent Trends in Squamous Cell Carcinoma of the Anus Incidence and Mortality in the United States, 2001-2015. J Natl Cancer Inst 2020; 112:829.</a></li><li><a class="nounderline abstract_t">Daling JR, Weiss NS, Klopfenstein LL, et al. Correlates of homosexual behavior and the incidence of anal cancer. JAMA 1982; 247:1988.</a></li><li><a class="nounderline abstract_t">Melbye M, Coté TR, Kessler L, et al. High incidence of anal cancer among AIDS patients. The AIDS/Cancer Working Group. Lancet 1994; 343:636.</a></li><li><a class="nounderline abstract_t">Goedert JJ, Coté TR, Virgo P, et al. Spectrum of AIDS-associated malignant disorders. Lancet 1998; 351:1833.</a></li><li><a class="nounderline abstract_t">Bower M, Powles T, Newsom-Davis T, et al. HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome? J Acquir Immune Defic Syndr 2004; 37:1563.</a></li><li><a class="nounderline abstract_t">Diamond C, Taylor TH, Aboumrad T, et al. Increased incidence of squamous cell anal cancer among men with AIDS in the era of highly active antiretroviral therapy. Sex Transm Dis 2005; 32:314.</a></li><li><a class="nounderline abstract_t">Cress RD, Holly EA. Incidence of anal cancer in California: increased incidence among men in San Francisco, 1973-1999. Prev Med 2003; 36:555.</a></li><li><a class="nounderline abstract_t">Peters RK, Mack TM. Patterns of anal carcinoma by gender and marital status in Los Angeles County. Br J Cancer 1983; 48:629.</a></li><li><a class="nounderline abstract_t">Daling JR, Weiss NS, Hislop TG, et al. Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med 1987; 317:973.</a></li><li><a class="nounderline abstract_t">Holly EA, Whittemore AS, Aston DA, et al. Anal cancer incidence: genital warts, anal fissure or fistula, hemorrhoids, and smoking. J Natl Cancer Inst 1989; 81:1726.</a></li><li><a class="nounderline abstract_t">Frisch M, Olsen JH, Bautz A, Melbye M. Benign anal lesions and the risk of anal cancer. N Engl J Med 1994; 331:300.</a></li><li><a class="nounderline abstract_t">Melbye M, Rabkin C, Frisch M, Biggar RJ. Changing patterns of anal cancer incidence in the United States, 1940-1989. Am J Epidemiol 1994; 139:772.</a></li><li><a class="nounderline abstract_t">Rabkin CS, Yellin F. Cancer incidence in a population with a high prevalence of infection with human immunodeficiency virus type 1. J Natl Cancer Inst 1994; 86:1711.</a></li><li><a class="nounderline abstract_t">Critchlow CW, Surawicz CM, Holmes KK, et al. Prospective study of high grade anal squamous intraepithelial neoplasia in a cohort of homosexual men: influence of HIV infection, immunosuppression and human papillomavirus infection. AIDS 1995; 9:1255.</a></li><li><a class="nounderline abstract_t">Frisch M, Glimelius B, van den Brule AJ, et al. Sexually transmitted infection as a cause of anal cancer. N Engl J Med 1997; 337:1350.</a></li><li><a class="nounderline abstract_t">Clifford GM, Georges D, Shiels MS, et al. A meta-analysis of anal cancer incidence by risk group: Toward a unified anal cancer risk scale. Int J Cancer 2021; 148:38.</a></li><li><a class="nounderline abstract_t">Northfelt DW, Swift PS, Palefsky JM. Anal neoplasia. Pathogenesis, diagnosis, and management. Hematol Oncol Clin North Am 1996; 10:1177.</a></li><li><a class="nounderline abstract_t">Tilston P. Anal human papillomavirus and anal cancer. J Clin Pathol 1997; 50:625.</a></li><li><a class="nounderline abstract_t">Bjørge T, Engeland A, Luostarinen T, et al. Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study. Br J Cancer 2002; 87:61.</a></li><li><a class="nounderline abstract_t">Daling JR, Madeleine MM, Johnson LG, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 2004; 101:270.</a></li><li><a class="nounderline abstract_t">Joseph DA, Miller JW, Wu X, et al. Understanding the burden of human papillomavirus-associated anal cancers in the US. Cancer 2008; 113:2892.</a></li><li><a class="nounderline abstract_t">Serup-Hansen E, Linnemann D, Skovrider-Ruminski W, et al. Human papillomavirus genotyping and p16 expression as prognostic factors for patients with American Joint Committee on Cancer stages I to III carcinoma of the anal canal. J Clin Oncol 2014; 32:1812.</a></li><li><a class="nounderline abstract_t">Zaki SR, Judd R, Coffield LM, et al. Human papillomavirus infection and anal carcinoma. Retrospective analysis by in situ hybridization and the polymerase chain reaction. Am J Pathol 1992; 140:1345.</a></li><li><a class="nounderline abstract_t">Palefsky JM, Holly EA, Gonzales J, et al. Detection of human papillomavirus DNA in anal intraepithelial neoplasia and anal cancer. Cancer Res 1991; 51:1014.</a></li><li><a class="nounderline abstract_t">Duggan MA, Boras VF, Inoue M, et al. Human papillomavirus DNA determination of anal condylomata, dysplasias, and squamous carcinomas with in situ hybridization. Am J Clin Pathol 1989; 92:16.</a></li><li><a class="nounderline abstract_t">Palefsky JM, Holly EA, Hogeboom CJ, et al. Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17:314.</a></li><li><a class="nounderline abstract_t">Machalek DA, Poynten M, Jin F, et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol 2012; 13:487.</a></li><li><a class="nounderline abstract_t">Williams GR, Lu QL, Love SB, et al. Properties of HPV-positive and HPV-negative anal carcinomas. J Pathol 1996; 180:378.</a></li><li><a class="nounderline abstract_t">Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011; 365:1576.</a></li><li><a class="nounderline abstract_t">Zhang ER, Pfeiffer RM, Austin A, et al. Impact of HIV on Anal Squamous Cell Carcinoma Rates in the United States, 2001-2015. J Natl Cancer Inst 2022; 114:1246.</a></li><li><a class="nounderline abstract_t">Palefsky JM, Gonzales J, Greenblatt RM, et al. Anal intraepithelial neoplasia and anal papillomavirus infection among homosexual males with group IV HIV disease. JAMA 1990; 263:2911.</a></li><li><a class="nounderline abstract_t">Palefsky JM, Holly EA, Ralston ML, et al. Anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual and bisexual men: prevalence and risk factors. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17:320.</a></li><li><a class="nounderline abstract_t">Palefsky JM, Holly EA, Ralston ML, et al. High incidence of anal high-grade squamous intra-epithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men. AIDS 1998; 12:495.</a></li><li><a class="nounderline abstract_t">Silverberg MJ, Lau B, Justice AC, et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis 2012; 54:1026.</a></li><li><a class="nounderline abstract_t">Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000; 92:1500.</a></li><li><a class="nounderline abstract_t">Caussy D, Goedert JJ, Palefsky J, et al. Interaction of human immunodeficiency and papilloma viruses: association with anal epithelial abnormality in homosexual men. Int J Cancer 1990; 46:214.</a></li><li><a class="nounderline abstract_t">Kiviat N, Rompalo A, Bowden R, et al. Anal human papillomavirus infection among human immunodeficiency virus-seropositive and -seronegative men. J Infect Dis 1990; 162:358.</a></li><li><a class="nounderline abstract_t">Williams AB, Darragh TM, Vranizan K, et al. Anal and cervical human papillomavirus infection and risk of anal and cervical epithelial abnormalities in human immunodeficiency virus-infected women. Obstet Gynecol 1994; 83:205.</a></li><li><a class="nounderline abstract_t">Sun XW, Kuhn L, Ellerbrock TV, et al. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 1997; 337:1343.</a></li><li><a class="nounderline abstract_t">Sobhani I, Vuagnat A, Walker F, et al. Prevalence of high-grade dysplasia and cancer in the anal canal in human papillomavirus-infected individuals. Gastroenterology 2001; 120:857.</a></li><li><a class="nounderline abstract_t">Frisch M, Melbye M, Møller H. Trends in incidence of anal cancer in Denmark. BMJ 1993; 306:419.</a></li><li><a class="nounderline abstract_t">Biggar RJ, Burnett W, Mikl J, Nasca P. Cancer among New York men at risk of acquired immunodeficiency syndrome. Int J Cancer 1989; 43:979.</a></li><li><a class="nounderline abstract_t">Selik RM, Rabkin CS. Cancer death rates associated with human immunodeficiency virus infection in the United States. J Natl Cancer Inst 1998; 90:1300.</a></li><li><a class="nounderline abstract_t">Biggar RJ, Horm J, Goedert JJ, Melbye M. Cancer in a group at risk of acquired immunodeficiency syndrome (AIDS) through 1984. Am J Epidemiol 1987; 126:578.</a></li><li><a class="nounderline abstract_t">Harnly ME, Swan SH, Holly EA, et al. Temporal trends in the incidence of non-Hodgkin's lymphoma and selected malignancies in a population with a high incidence of acquired immunodeficiency syndrome (AIDS). Am J Epidemiol 1988; 128:261.</a></li><li><a class="nounderline abstract_t">Colón-López V, Shiels MS, Machin M, et al. Anal Cancer Risk Among People With HIV Infection in the United States. J Clin Oncol 2018; 36:68.</a></li><li><a class="nounderline abstract_t">Crum-Cianflone NF, Hullsiek KH, Marconi VC, et al. Anal cancers among HIV-infected persons: HAART is not slowing rising incidence. AIDS 2010; 24:535.</a></li><li><a class="nounderline abstract_t">Piketty C, Selinger-Leneman H, Bouvier AM, et al. Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the french hospital database on HIV. J Clin Oncol 2012; 30:4360.</a></li><li><a class="nounderline abstract_t">Palefsky JM, Holly EA, Ralston ML, Jay N. Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J Infect Dis 1998; 177:361.</a></li><li><a class="nounderline abstract_t">Unger ER, Vernon SD, Lee DR, et al. Human papillomavirus type in anal epithelial lesions is influenced by human immunodeficiency virus. Arch Pathol Lab Med 1997; 121:820.</a></li><li><a class="nounderline abstract_t">Bertisch B, Franceschi S, Lise M, et al. Risk factors for anal cancer in persons infected with HIV: a nested case-control study in the Swiss HIV Cohort Study. Am J Epidemiol 2013; 178:877.</a></li><li><a class="nounderline abstract_t">Penn I. Incidence and treatment of neoplasia after transplantation. J Heart Lung Transplant 1993; 12:S328.</a></li><li><a class="nounderline abstract_t">Penn I. Cancers of the anogenital region in renal transplant recipients. Analysis of 65 cases. Cancer 1986; 58:611.</a></li><li><a class="nounderline abstract_t">Arends MJ, Benton EC, McLaren KM, et al. Renal allograft recipients with high susceptibility to cutaneous malignancy have an increased prevalence of human papillomavirus DNA in skin tumours and a greater risk of anogenital malignancy. Br J Cancer 1997; 75:722.</a></li><li><a class="nounderline abstract_t">Sillman F, Stanek A, Sedlis A, et al. The relationship between human papillomavirus and lower genital intraepithelial neoplasia in immunosuppressed women. Am J Obstet Gynecol 1984; 150:300.</a></li><li><a class="nounderline abstract_t">Sillman FH, Sedlis A. Anogenital papillomavirus infection and neoplasia in immunodeficient women: an update. Dermatol Clin 1991; 9:353.</a></li><li><a class="nounderline abstract_t">Rabkin CS, Biggar RJ, Melbye M, Curtis RE. Second primary cancers following anal and cervical carcinoma: evidence of shared etiologic factors. Am J Epidemiol 1992; 136:54.</a></li><li><a class="nounderline abstract_t">Holmes F, Borek D, Owen-Kummer M, et al. Anal cancer in women. Gastroenterology 1988; 95:107.</a></li><li><a class="nounderline abstract_t">Daling JR, Sherman KJ, Hislop TG, et al. Cigarette smoking and the risk of anogenital cancer. Am J Epidemiol 1992; 135:180.</a></li><li><a class="nounderline abstract_t">Frisch M, Glimelius B, Wohlfahrt J, et al. Tobacco smoking as a risk factor in anal carcinoma: an antiestrogenic mechanism? J Natl Cancer Inst 1999; 91:708.</a></li><li><a class="nounderline abstract_t">Sood AK. Cigarette smoking and cervical cancer: meta-analysis and critical review of recent studies. Am J Prev Med 1991; 7:208.</a></li></ol></div><div id="topicVersionRevision">Topic 2474 Version 53.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36633525" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Cancer statistics, 2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36441987" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : State Variation in Squamous Cell Carcinoma of the Anus Incidence and Mortality, and Association With HIV/AIDS and Smoking in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36441987" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : State Variation in Squamous Cell Carcinoma of the Anus Incidence and Mortality, and Association With HIV/AIDS and Smoking in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36441987" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : State Variation in Squamous Cell Carcinoma of the Anus Incidence and Mortality, and Association With HIV/AIDS and Smoking in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8823332" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9164216" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9164216" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6692319" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Epidermoid cancer of the anorectum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2765832" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Squamous cell carcinoma of the anus at one hospital from 1948 to 1984.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3966647" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Epidermoid cancer of the anal margin. Pathologic features, treatment, and clinical results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15241824" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19156144" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : An analysis of temporal and generational trends in the incidence of anal and other HPV-related cancers in Southeast England.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23042932" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Impact of the HIV epidemic on the incidence rates of anal cancer in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19293308" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Sex disparities in cancer incidence by period and age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27789668" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : International trends in anal cancer incidence rates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31742639" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Recent Trends in Squamous Cell Carcinoma of the Anus Incidence and Mortality in the United States, 2001-2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7062503" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Correlates of homosexual behavior and the incidence of anal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7906812" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : High incidence of anal cancer among AIDS patients. The AIDS/Cancer Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9652666" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Spectrum of AIDS-associated malignant disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15577408" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15849533" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Increased incidence of squamous cell anal cancer among men with AIDS in the era of highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12689800" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Incidence of anal cancer in California: increased incidence among men in San Francisco, 1973-1999.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6639856" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Patterns of anal carcinoma by gender and marital status in Los Angeles County.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2821396" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Sexual practices, sexually transmitted diseases, and the incidence of anal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2810388" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Anal cancer incidence: genital warts, anal fissure or fistula, hemorrhoids, and smoking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8022440" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Benign anal lesions and the risk of anal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8178790" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Changing patterns of anal cancer incidence in the United States, 1940-1989.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7966400" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Cancer incidence in a population with a high prevalence of infection with human immunodeficiency virus type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8561979" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Prospective study of high grade anal squamous intraepithelial neoplasia in a cohort of homosexual men: influence of HIV infection, immunosuppression and human papillomavirus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9358129" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Sexually transmitted infection as a cause of anal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32621759" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A meta-analysis of anal cancer incidence by risk group: Toward a unified anal cancer risk scale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8880204" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Anal neoplasia. Pathogenesis, diagnosis, and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9301544" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Anal human papillomavirus and anal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12085257" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15241823" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18980293" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Understanding the burden of human papillomavirus-associated anal cancers in the US.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24821878" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Human papillomavirus genotyping and p16 expression as prognostic factors for patients with American Joint Committee on Cancer stages I to III carcinoma of the anal canal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1318640" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Human papillomavirus infection and anal carcinoma. Retrospective analysis by in situ hybridization and the polymerase chain reaction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1846314" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Detection of human papillomavirus DNA in anal intraepithelial neoplasia and anal cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2546419" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Human papillomavirus DNA determination of anal condylomata, dysplasias, and squamous carcinomas with in situ hybridization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9525431" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22445259" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9014857" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Properties of HPV-positive and HPV-negative anal carcinomas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22029979" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : HPV vaccine against anal HPV infection and anal intraepithelial neoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35575389" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Impact of HIV on Anal Squamous Cell Carcinoma Rates in the United States, 2001-2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2160023" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Anal intraepithelial neoplasia and anal papillomavirus infection among homosexual males with group IV HIV disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9525432" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual and bisexual men: prevalence and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9543448" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : High incidence of anal high-grade squamous intra-epithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22291097" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10995805" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2166710" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Interaction of human immunodeficiency and papilloma viruses: association with anal epithelial abnormality in homosexual men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1973695" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Anal human papillomavirus infection among human immunodeficiency virus-seropositive and -seronegative men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8290181" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Anal and cervical human papillomavirus infection and risk of anal and cervical epithelial abnormalities in human immunodeficiency virus-infected women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9358128" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Human papillomavirus infection in women infected with the human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11231940" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Prevalence of high-grade dysplasia and cancer in the anal canal in human papillomavirus-infected individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8461721" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Trends in incidence of anal cancer in Denmark.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2732009" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Cancer among New York men at risk of acquired immunodeficiency syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9731737" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Cancer death rates associated with human immunodeficiency virus infection in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3631049" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Cancer in a group at risk of acquired immunodeficiency syndrome (AIDS) through 1984.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3394695" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Temporal trends in the incidence of non-Hodgkin's lymphoma and selected malignancies in a population with a high incidence of acquired immunodeficiency syndrome (AIDS)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29140774" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Anal Cancer Risk Among People With HIV Infection in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19926961" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Anal cancers among HIV-infected persons: HAART is not slowing rising incidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23091098" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the french hospital database on HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9466522" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9278609" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Human papillomavirus type in anal epithelial lesions is influenced by human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23900553" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Risk factors for anal cancer in persons infected with HIV: a nested case-control study in the Swiss HIV Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8312352" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Incidence and treatment of neoplasia after transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3524788" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Cancers of the anogenital region in renal transplant recipients. Analysis of 65 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9043031" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Renal allograft recipients with high susceptibility to cutaneous malignancy have an increased prevalence of human papillomavirus DNA in skin tumours and a greater risk of anogenital malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6091459" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The relationship between human papillomavirus and lower genital intraepithelial neoplasia in immunosuppressed women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1647909" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Anogenital papillomavirus infection and neoplasia in immunodeficient women: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1329500" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Second primary cancers following anal and cervical carcinoma: evidence of shared etiologic factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2836255" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Anal cancer in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1311142" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Cigarette smoking and the risk of anogenital cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10218509" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Tobacco smoking as a risk factor in anal carcinoma: an antiestrogenic mechanism?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1836735" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Cigarette smoking and cervical cancer: meta-analysis and critical review of recent studies.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
